Psychiatry and Health Behavior, Augusta University, 997 St. Sebastian Way, Augusta, GA, 30912, USA.
Carl R. Darnall Army Medical Center, 36065 Santa Fe Ave, Fort Cavazos, TX, 76544, USA.
Harm Reduct J. 2023 Oct 5;20(1):144. doi: 10.1186/s12954-023-00878-8.
Over 109,000 people in the USA died from a drug overdose in 2022. More alarming is the amount of drug overdose deaths involving synthetic opioids other than methadone (SOOM), primarily fentanyl. From 2015 to 2020, the number of drug overdose deaths from SOOM increased 5.9-fold. SOOM are commonly being found in many other drugs without the user's knowledge. Given the alarming number of overdose deaths from illicit drugs with SOOM, naloxone should be prescribed for all persons using illicit drugs regardless of if they knowingly use opioids. How often providers prescribe naloxone for these patients remains unknown. The aim of this study is to determine the rate of naloxone prescriptions given to patients with any substance use disorder, including when the patient has a urine drug screen positive for fentanyl. Secondary aims include determining what patient factors are associated with receiving a naloxone prescription.
The design was a single-center retrospective cohort study on patients that presented to the Augusta University Medical Center emergency department between 2019 through 2021 and had an ICD-10 diagnosis of a substance use disorder. Analyses were conducted by logistic regression and t-test or Welch's t-test.
A total of 10,510 emergency department visits were by 6787 patients. Naloxone was prescribed in 16.3% of visits with an opioid-related discharge diagnosis and 8.4% of visits with a non-opioid substance use-related discharge diagnosis and a urine drug screen positive for fentanyl. Patients with a fentanyl positive urine drug screen had higher odds of receiving a naloxone prescription (aOR 5.80, 95% CI 2.76-12.20, p < 0.001). Patients with a psychiatric diagnosis had lower odds of being prescribed naloxone (aOR 0.51, p = 0.03). Patients who received naloxone had a lower number of visits (mean 1.23 vs. 1.55, p < 0.001). Patients with a urine drug screen positive for cocaine had higher odds of frequent visits (aOR 3.07, p = 0.01).
Findings should remind providers to prescribe naloxone to all patients with a substance use disorder, especially those with a positive fentanyl urine drug screen or a co-occurring psychiatric condition. Results also show that cocaine use continues to increase healthcare utilization.
2022 年,美国有超过 109000 人死于药物过量。更令人震惊的是,涉及除美沙酮以外的合成阿片类药物(SOOM)的药物过量死亡人数,主要是芬太尼。从 2015 年到 2020 年,SOOM 药物过量死亡人数增加了 5.9 倍。SOOM 通常在许多其他药物中被发现,而使用者并不知道。鉴于含有 SOOM 的非法药物导致的过量死亡人数众多,无论患者是否明知使用阿片类药物,都应向所有使用非法药物的患者开出处方纳洛酮。目前尚不清楚提供者为这些患者开具纳洛酮的频率。本研究旨在确定对任何物质使用障碍患者(包括尿液药物检测呈芬太尼阳性的患者)开具纳洛酮处方的比率。次要目标包括确定哪些患者因素与接受纳洛酮处方有关。
这是一项单中心回顾性队列研究,研究对象为 2019 年至 2021 年期间在奥古斯塔大学医疗中心急诊就诊且 ICD-10 诊断为物质使用障碍的患者。分析采用逻辑回归和 t 检验或 Welch's t 检验进行。
共有 10510 次急诊就诊,涉及 6787 名患者。在阿片类药物相关出院诊断的就诊中,有 16.3%的就诊开具了纳洛酮处方,在非阿片类物质使用相关出院诊断且尿液药物检测呈芬太尼阳性的就诊中,有 8.4%的就诊开具了纳洛酮处方。尿液药物检测呈芬太尼阳性的患者开处纳洛酮的可能性更高(优势比 5.80,95%CI 2.76-12.20,p<0.001)。有精神科诊断的患者开处纳洛酮的可能性较低(优势比 0.51,p=0.03)。接受纳洛酮的患者就诊次数较少(平均 1.23 次与 1.55 次,p<0.001)。尿液药物检测可卡因阳性的患者就诊更频繁的可能性更高(优势比 3.07,p=0.01)。
研究结果应提醒医务人员向所有物质使用障碍患者开出处方纳洛酮,尤其是那些尿液芬太尼药物检测阳性或同时伴有精神疾病的患者。结果还表明,可卡因的使用仍在增加医疗保健的利用率。